Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system

  title={Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system},
  author={Marinos C. Dalakas},
  journal={Therapeutic Advances in Neurological Disorders},
  • M. Dalakas
  • Published 14 September 2018
  • Medicine, Biology
  • Therapeutic Advances in Neurological Disorders
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications. It is a phenomenon of immunological twist when immunotherapy against co-stimulatory molecules activates previously normal T cells to kill tumor cells but, in so doing, the T cells become unrestrained, triggering other autoimmune diseases for which conventional immunotherapy is needed. The most common autoimmune neurological diseases… 

Figures and Tables from this paper

Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of care in the treatment of various tumor types. Despite the favorable results in terms of oncological
A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies
Overall, the survey suggested a causal relationship between neurological irAEs and autoantibodies and detection of autoantIBodies may help to diagnose neurological ir AEs and inform their clinical management.
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
The aim of this review was to summarize the current knowledge about the pathogenic mechanisms, clinical manifestations, and therapeutic recommendations regarding the main forms of neurotoxicity related to checkpoint inhibitors.
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
IrAEs associated with CAR-T and ICPI therapy constitute new entities and early identification and treatment are essential to optimize the functional outcome and further oncologic management of the patient.
Neurological complications of cancer immunotherapy.
Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients
The review focuses on increasing events of neuropathy associated with immunecheckpoint inhibitors, which is one of the rare neurological irAEs, therefore, the least reviewed.
Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors
The frequency of spinal cord involvement and neuronal toxicity after cancer immunotherapy is very low and requires an extensive diagnostic workup to differentiate between disease progression and side effects.
Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosis
A patient with multiple sclerosis who underwent immune checkpoint inhibitor therapy with pembrolizumab for metastatic malignant melanoma who had a complete response to treatment at the cost of MS relapse, which was managed with high-dose steroids.
Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy
A 56-year-old woman who had received nivolumab for stage 4 renal cell carcinoma subsequently developed altered behaviour, memory deficits and worsening of previously stable epilepsy, and there were anti-Ma2 antibodies in both serum and cerebrospinal fluid.


Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Although rare, neurological adverse events require prompt recognition and treatment to avoid substantial morbidity and have shown promising results in cancer but can possibly induce autoimmune disorders.
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
The mechanisms of action of ICIs are introduced and their adverse effects on the CNS are reviewed, highlighting the importance of early detection of these neurotoxic effects, which should be distinguished from brain metastasis.
Neurological toxicities associated with immune-checkpoint inhibitors
ICI-associated irAEs constitute a new group of neurologic complications of systemic anticancer therapies, although potentially severe, these rare neurologic toxicities are often responsive to immune-modulating therapies.
Neurologic complications of immune checkpoint inhibitors
This series highlights the very broad spectrum of neurological complications of ICPIs, emphasizes the need for expedited diagnosis and suggests that withholding treatment early, accompanied with steroid therapy, carries the potential of complete resolution of the neurological immune-mediated condition.
Endocrine side effects induced by immune checkpoint inhibitors.
Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease in patients affected by advanced cutaneous melanoma.
Pembrolizumab‐Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
  • G. Hunter, C. Voll, C. Robinson
  • Medicine, Biology
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2009
The first case of autoimmune polymyositis in association with ipilimumab treatment is reported, potential implications of CTLA-4 in neurologic disease and therapeutics are discussed, and IRAE after ipilitationab treatment are associated with an improved prognosis, and outcome seems to correlate with the grade of AE.